AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 291%
Price (€) 1.85
Market Cap (€M) 83.1
Perf. 1W: -5.32%
Perf. 1M: 3.82%
Perf. 3M: -6.57%
Perf Ytd: -16.7%
10 day relative perf. to stoxx600: -2.47%
20 day relative perf. to stoxx600: 4.16%
EPS change18/04/2019 11:00

The 2018 bonds fully converted

Change in EPS2019 : € -0.48 vs -0.51ns
2020 : € -0.34 vs -0.39ns

We have increased the total number of shares (from 13.6m at year-end 2018 to 18.4m in March 2019) following the conversion of all convertible bonds issued last year, which by the way confirms shareholders’ confidence in the company. The valuation does not significantly change (dilution on one side, a lower net debt position on the other one), but of course the apparent loss per share is smaller over the next two years. No other changes to our model.



Updates

18 Apr 19 EPS change
The 2018 bonds fully converted

18 Mar 19 EPS change
No major change post FY18 results

15 Mar 19 Earnings/sales releases
Slowly but surely

04 Feb 19 Financing issue
Some extra non-dilutive financing

24 Dec 18 EPS change
Adjustment in the number of shares

28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

.